Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis president joins Qu Biologics

Robert Pelzer is appointed board member at immunotherapy specialists

Qu Biologics Robert Pelzer

Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.

Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.

He was previously global general counsel and head of legal services for Novartis at a corporate level.

Before joining Novartis in 2002, he spent several years at DuPont Pharmaceuticals, serving as general counsel and senior VP.

His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease.

“Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development,” said CEO of Qu Biologics Dr Hal Gunn, who also noted that Pelzer will help develop relationships with potential pharma partners.

18th June 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics